Skip to main navigation Skip to search Skip to main content

Chronisch bullöse dermatose des kindesalters. Langzeittherapie über 8 jahre mit 4,4'-diaminodiphenylsulfon

Translated title of the contribution: Chronic bullous disease of childhood. Long-term therapy over 8 years with 4,4'-diaminodiphenylsulfone

D. Pirkhammer*, D. Zillikens, D. Födinger, P. Zimmermann, K. Rappersberger

*Corresponding author for this work

Abstract

A 3-year-old boy presented with a generalized bullous disease, clinically strongly indicative of chronic bullous disease of childhood (CBDC). The diagnosis was confirmed by histopathology and further verified by several immunological and biochemical examinations. Direct immunofluorescence (IF) of perilesional skin revealed in vivo bound IgA-autoantibodies (aabs) in a linear pattern along the basement membrane zone; indirect IF revealed circulating IgA-aabs bound to the roof of "split skin" preparations of healthy human skin; immunoblotting of epidermal protein extracts showed that the aabs bound to a 97KD/120KD protein. Therapy with 4,4'-diaminodiphenylsulfone (DADPS, 2 mg/kg /daily), combined with prednisolone for the first month, was initiated, and promptly led to complete remission. Two attempts to stop DADPS treatment after 3 and 5 years of continuous therapy were followed by prompt recurrences. The boy is now 8 years old; with continuous DADPS therapy (1 mg/kg body weight/d), he displays regular physical and intellectual development.

Translated title of the contributionChronic bullous disease of childhood. Long-term therapy over 8 years with 4,4'-diaminodiphenylsulfone
Original languageGerman
JournalHautarzt
Volume63
Issue number8
Pages (from-to)644-647
Number of pages4
ISSN0017-8470
DOIs
Publication statusPublished - 01.08.2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Chronic bullous disease of childhood. Long-term therapy over 8 years with 4,4'-diaminodiphenylsulfone'. Together they form a unique fingerprint.

Cite this